WO2020130164A1 - Oral hygiene composition - Google Patents

Oral hygiene composition Download PDF

Info

Publication number
WO2020130164A1
WO2020130164A1 PCT/KR2018/016051 KR2018016051W WO2020130164A1 WO 2020130164 A1 WO2020130164 A1 WO 2020130164A1 KR 2018016051 W KR2018016051 W KR 2018016051W WO 2020130164 A1 WO2020130164 A1 WO 2020130164A1
Authority
WO
WIPO (PCT)
Prior art keywords
group
disease
oral
eugenol
composition
Prior art date
Application number
PCT/KR2018/016051
Other languages
French (fr)
Korean (ko)
Inventor
유정헌
이상화
임준만
Original Assignee
주식회사 엘지생활건강
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 주식회사 엘지생활건강 filed Critical 주식회사 엘지생활건강
Priority to PCT/KR2018/016051 priority Critical patent/WO2020130164A1/en
Publication of WO2020130164A1 publication Critical patent/WO2020130164A1/en

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
    • A61K8/20—Halogens; Compounds thereof
    • A61K8/21—Fluorides; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
    • A61K8/25—Silicon; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/34—Alcohols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q11/00—Preparations for care of the teeth, of the oral cavity or of dentures; Dentifrices, e.g. toothpastes; Mouth rinses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings

Definitions

  • the present invention relates to an oral hygiene composition having excellent preventive and therapeutic effects on bad breath, toothache, stomatitis, gingivitis, periodontitis, syringitis, dental caries, periodontal disease, pulp disease and apical disease.
  • Dental caries and periodontal disease among oral diseases are known as the main factors that cause various clinical symptoms such as pain, chewing dysfunction, periodontal tissue destruction, bad breath and pain, and cause tooth loss.
  • the causative factor is increasing.
  • antibiotics have the disadvantage that they can be used only as therapeutic agents because they are difficult to use for a long time because they can induce the appearance of mycobacterium-resistant bacteria and alternation of oral bacteria in addition to systemic side effects on the body.
  • antibacterial agents used in oral cleansing agents include saline guinarine, listerine, pyroxide, chlorhexidine, etc. Saengquinarine has an unclear effect on bacteria in the oral cavity and is more unclear about the treatment effect in periodontal disease.
  • Listerine is a main component of alcohol, which has a temporary effect in the oral cavity, but has some bacteriostatic effects, but also has a disadvantage in that it may have a harmful effect on tissues when used for a long time.
  • Pyroxide (Peroxide) which is being added for the whitening effect, has a poisonous effect on bacteria, but at the same time has a poisonous effect on human tissues, and also has safety problems, and sometimes bacteria resistant to pyroxide appear in bacteria.
  • chlorhexidine is known to be the best among the formulations known to date as a preventive and therapeutic agent for periodontal disease in addition to inhibition of plaque formation, but it has a strong irritating and odorous side effect.
  • mycosis which can also cause carcinogenicity, and limited use in pregnant women.
  • the present invention is to provide an oral hygiene composition excellent in antibacterial effect, excellent in the prevention, improvement and treatment of bad breath, toothache, stomatitis, gingivitis, periodontitis, syringitis, dental caries, periodontal disease, pulp disease and apical disease.
  • the present invention provides an oral hygiene composition comprising any one or more selected from the group consisting of saccharin, fluorine, calcium carbonate and silica and eugenol as an active ingredient.
  • the composition of the present invention is characterized in that it is for preventing, alleviating or treating oral diseases.
  • the oral disease is characterized in that it is at least one selected from the group consisting of bad breath, toothache, stomatitis, gingivitis, periodontitis, acute teeth, dental caries, periodontal disease, pulp disease and apical disease.
  • any one or more selected from the group consisting of the saccharin, fluorine, calcium carbonate, and silica is characterized by being mixed with eugenol in a weight ratio of 1:0.1 to 10.
  • any one or more selected from the group consisting of the saccharin, fluorine, calcium carbonate and silica is characterized in that it contains 0.001 to 0.1% by weight based on the total weight of the composition.
  • the eugenol is characterized in that it comprises 0.001 to 0.1% by weight based on the total weight of the composition.
  • the composition is characterized in that it has an antibacterial effect in the genus Streptococcus (Streptococcus) or in Porphyromonas (Porphyromonas).
  • Streptococcus genus or Porphyromonas genus Streptococcus mutans Streptococcus sanguis, Streptococcus sanguinis, Streptococcus sanguinis, Streptococcus salivaus Streptococcus salivariussubsp. thermophils
  • one or more selected from the group consisting of Porphyromonas gingivalis one or more selected from the group consisting of Porphyromonas gingivalis.
  • an oral product comprising the aforementioned oral hygiene composition.
  • the oral product of the present invention is characterized by being selected from the group consisting of toothpaste, gargling product, gum, oral spray, oral ointment, mouthwash and mouthwash.
  • the present invention has excellent antibacterial effect, exerts excellent effects on the prevention, improvement and treatment of bad breath, toothache, stomatitis, gingivitis, periodontitis, syringitis, dental caries, periodontal disease, pulp disease and apical disease.
  • the present invention is oral hygiene containing any one or more selected from the group consisting of saccharin (Sacharine), fluorine (F), calcium carbonate (CaC0 3 ) and silica (Silica) and eugenol (Eugenol) Provided is a composition.
  • the composition of the present invention is characterized in that it is for preventing, alleviating or treating oral diseases.
  • the oral disease is, for example, but is not limited to bad breath, acute teeth, dental caries, gingivitis, periodontitis, mucosal ulcers in the oral cavity, and apical disease.
  • prevention refers to any act of suppressing or delaying the disease using the oral hygiene composition.
  • treatment refers to all actions in which symptoms of the disease are alleviated or cured using the oral hygiene composition.
  • treating means that the symptoms of oral disease such as the above are reduced or softened, and can be understood as a broad concept including improvement, prevention, and treatment.
  • the term “improvement” can be understood as a broad concept that means to recover symptoms close to the original condition by treating oral diseases and the like.
  • the oral disease is characterized in that it is at least one selected from the group consisting of bad breath, toothache, stomatitis, gingivitis, periodontitis, acute teeth, dental caries, periodontal disease, pulp disease and apical disease.
  • halt breath is not limited to this, but due to acquired systemic disease, protein in saliva, food debris, etc., is decomposed by microorganisms in the oral cavity to decompose, resulting in odor It can be caused by generating substances.
  • the primary cause of bad breath is not limited to microorganisms in the oral cavity, but is not limited to the genus Streptococcus , genus Porphyromonas , Actinomyces genus, Actinobacillus genus, etc. This can be.
  • toothache most commonly occurs due to structural damage to the teeth, where dental nerves, which are usually well protected by dentin and enamel, are not only the result of caries, tooth cracking, tooth root exposure or enamel erosion. In addition, it is exposed to external stimuli by gingival diseases, abscesses or ambushes.
  • the term “stomatitis” is also referred to as mucosal ulcer in the oral cavity, but is not limited thereto, due to infection by bacteria, viruses, fungi, etc. in the oral cavity (hymen, gums, lips, cheeks inside) Etc.) refers to a disease in which inflammation occurs, and the bacteria may be bacteria such as the genus Streptococcus and the genus Porphyromonas.
  • the term “gingivitis” and “gingivitis” are not limited to this, but the bacteria, such as the genus Streptococcus, Porphyromonas, which are present in the subgingival plaque, have appropriate growth conditions. When it is formed, it may be an oral disease that causes inflammation of the gums by developing an infection in the soft tissues of the gingival area and developing a periodontal disease of gingivitis or periodontitis.
  • the term "syrinyi” means, but is not limited to, cavities or other pathological causes, apart from external stimulation, refers to any phenomenon that appears sharp, temporary or persistent pain.
  • the external stimulus usually refers to a temperature stimulus, and usually complains of a symptom in a cold temperature stimulus.
  • pain may also be caused by stimulation such as drying of the teeth, contact with foreign substances, osmotic pressure through sweet or sour food. It may appear throughout the entire tooth, and may be limited to certain areas, such as the maxilla or mandible, or the right or left side, and may be accompanied by dentin hyperesthesia, caries, and pulp inflammation.
  • the exposure of the mouth of the ivory tubule may be considered.
  • enamel or cementite is destroyed and the entrance of the ivory tubules is exposed to the outside, stimulation is transmitted to the pulp by the cell processes, nerves, and dentin fluid of the ivory tubules, and pain can be felt.
  • tooth caries refers to a lesion in which the hard tissue of a tooth is destroyed by bacteria (Streptococcus mutans, etc.) in the dental bacterial membrane attached to the surface of the tooth, an inorganic component of hemorrhoids by organic acids produced by bacteria (Calcium salt) is demineralized, and the organic component is decomposed again by enzymes from bacteria.
  • bacteria Streptococcus mutans, etc.
  • Calcium salt organic acids produced by bacteria
  • the bacteria that cause dental caries may be of the genus Streptococcus , of the genus Porphyromonas , and the like.
  • gingivitis is divided into gingivitis and periodontitis
  • gingivitis is an inflammatory lesion confined to the gingiva
  • periodontitis is a lesion occurring on the periodontal ligament and alveolar bone including gingivitis.
  • periodontal disease is divided into acute periodontitis and periodontal disease.
  • the term definition is correct in terms of the location where apical periodontitis occurs, it is most often referred to as apical disease in clinical practice.
  • the term "dimension disease” is divided into inflammatory lesions and non-inflammatory lesions, and inflammatory lesions include degenerative lesions such as pulpitis, non-inflammatory lesions, atrophy, degeneration, and necrosis.
  • the pulp is a plastic connective tissue with blood vessels and nerves distributed around it, surrounded by calcified dentin. During inflammation, blood vessels become congested and pulp tissue swells due to edema, which increases the internal pressure of the pulp, so inflammation of the pulp tissue progresses faster and pain is worse than other tissues.
  • apical disease is an inflammatory lesion occurring in the periodontal tissue around the apical tip, which occurs when there is insufficient open-mouth pulpitis, pulp necrosis or pulp gangrene, root canal treatment, or low toxicity bacteria.
  • the oral hygiene composition of the present invention is any one or more selected from the group consisting of saccharin, fluorine, calcium carbonate, and silica eugenol and a weight ratio of 1: 0.1 to 10, specifically 1: 0.5 to It may be included in a weight ratio of 5, more specifically 1: a weight ratio of 0.3 to 3, and most specifically, a weight ratio of 1:1.
  • any one or more selected from the group consisting of saccharin, fluorine, calcium carbonate and silica is 0.001 to 0.1% by weight, specifically 0.001 to 0.05% by weight, more specifically 0.005 to 0.01, based on the total weight of the composition It may be included in weight percent.
  • the ratio of the remaining components compared to any one component is 1:0.1 to It may be included in a weight ratio of 10, specifically 1: 0.1 to 5, and more specifically 1: 0.5 to 3.
  • eugenol may be included in an amount of 0.001 to 0.05% by weight, specifically 0.001 to 0.05% by weight, and more specifically 0.005 to 0.01% by weight based on the total weight of the composition.
  • any one or more selected from the group consisting of saccharin, fluorine, calcium carbonate and silica and eugenol when included in the composition of the present invention any one selected from the group consisting of saccharin, fluorine, calcium carbonate and silica
  • the ratio of eugenol may be included in a weight ratio of 1:0.1 to 10, specifically 1:0.1 to 5, and more specifically 1:0.5 to 3.
  • the oral hygiene composition of the present invention has an excellent antibacterial effect in Streptococcus or Porphyromonas and has excellent effects in preventing and treating oral diseases.
  • the oral hygiene composition of the present invention includes Streptococcus or Streptococcus mutans, Streptococcus sanguis, Streptococcus sanguinis, Streptococcus sanguinis, Streptococcus sanguinis It can exert an antibacterial effect on one or more selected from the group consisting of Streptococcus salivariussubsp. thermophils, and Porphyromonasgingivalis.
  • Oral hygiene composition of the present invention in addition to the above-mentioned components, as a component in general according to the formulation and purpose of use, we may further include a wetting agent, abrasives, agonists, sweeteners, pH adjusting agents, preservatives, binders, flavoring agents, foaming agents and the like. .
  • Wetting agents are used alone or in a mixture of concentrated glycerin, glycerin, sorbitol aqueous solution, amorphous sorbitol aqueous solution, polyethylene glycols, and propylene glycol, and the amount used may be 1 to 70% by weight based on the total weight of the oral hygiene composition .
  • the abrasive is selected from the group consisting of precipitated silica, silica gel, zirconium silicate, calcium monohydrogen phosphate, calcium monohydrogen phosphate, hydrous alumina, light calcium carbonate, heavy calcium carbonate, calcium pyrophosphate, insoluble metaphosphate, and aluminum silicate. Etc. can be used.
  • the amount of the abrasive may be generally 1 to 60% by weight based on the total weight of the oral hygiene composition.
  • additives used in a small amount may include sweeteners, pH adjusters, preservatives, colorants, and binders as commonly used components.
  • binder sodium carboxymethylcellulose, carbomer, carrageenan, xanthan gum, alginate, and the like can be used.
  • foaming agent anionic and nonionic surfactants such as sodium alkylsulfate, sodium lauryl sulfate, sucrose fatty acid ester, and sorbitan fatty acid ester can be used. It can be used alone or in combination of two or more.
  • the amount of the binder used is generally 0.1 to 3% by weight based on the total weight of the oral hygiene composition, and may preferably be 0.5 to 2% by weight.
  • Saccharin, xylitol, erythritol, aspartame, etc. may be used as the sweetener, and the amount of the sweetener may be 0.05 to 2% by weight based on the total weight of the oral hygiene composition.
  • sodium phosphate sodium phosphate, disodium phosphate, citric acid, triethanolamine, and the like can be used.
  • benzoic acid methylparaben, propylparaben, sodium benzoate, etc.
  • benzoic acid methylparaben, propylparaben, sodium benzoate, etc.
  • benzoic acid methylparaben, propylparaben, sodium benzoate, etc.
  • a fragrance peppermint oil, spearmint oil, and menthol may be used in combination, and enzymes such as dextranase may be used as other additives.
  • foaming agent anionic surfactant sodium lauryl sulfate, copolymer of nonionic surfactant polyoxyethylene polyoxypropylene (poloxamer), polyoxyethylene cured castor oil, polyoxyethylene sorbitan fatty acid ester, etc. may be used. .
  • the amount of the foaming agent is generally 0.5 to 5% by weight based on the total weight of the oral hygiene composition, preferably 0.5 to 3.5% by weight.
  • the present invention provides an oral hygiene composition for preventing or improving oral diseases comprising eugenol and any one or more selected from the group consisting of saccharin, fluorine, calcium carbonate and silica, which can be used for oral hygiene.
  • the oral hygiene composition include a food composition and a pharmaceutical composition (including quasi-drug composition), specifically, toothpaste, mouthwash, oral spray, oral ointment, gum, and the like.
  • a food composition for preventing or improving oral diseases comprising at least one selected from the group consisting of saccharin, fluorine, calcium carbonate, and silica and eugenol as an active ingredient.
  • examples of the food composition of the present invention include food, food additives, beverages or beverage additives.
  • the food composition of the present invention can exert a preventive and improving effect on any one or more oral diseases selected from the group consisting of bad breath, toothache, stomatitis, gingivitis, periodontitis, sirin, dental caries, periodontal disease, pulp disease and apical disease have.
  • a pharmaceutical composition for the prevention, improvement or treatment of oral diseases comprising at least one selected from the group consisting of saccharin, fluorine, calcium carbonate and silica and eugenol as an active ingredient.
  • the pharmaceutical composition of the present invention prevents, improves and treats at least one oral disease selected from the group consisting of bad breath, toothache, stomatitis, gingivitis, periodontitis, syringitis, dental caries, periodontal disease, pulp disease and apical disease Can be exercised.
  • an oral product comprising the aforementioned oral hygiene composition.
  • the oral hygiene composition according to the present invention is an oral hygiene composition that can be generally included in products manufactured and marketed for oral health, and there is no limitation on the applied oral products.
  • the oral product of the present invention is characterized by being selected from the group consisting of toothpaste, gargling product, gum, oral spray, oral ointment, mouthwash and mouthwash.
  • the paper disk test method is used to determine whether it has the effect of inhibiting strains using Gram-positive bacteria Streptococcus mutans and Gram-negative bacteria Porphyromonas gingivalis , which are representative caries and dental periodontal bacteria. Antibacterial activity test was conducted.
  • Each of the above bacteria after cultivating activity under the optimum culture conditions in Table 1, was cultured for 4 to 6 hours in the optimum medium of each bacterium to increase the turbidity of the culture medium in Macfarland turbidity No. After adjusting to 0.5 (1.5x10 8 ), 0.1 ml was spread evenly. After sterilizing paper disks (Whatman no.5 paper, 8mm diameter), the total concentration of treatment of each material was inoculated at a concentration of 10mg/disc and absorbed and dried for 1 hour. After culturing 24-48 hours at the optimum temperature of each bacterium, the size (diameter mm) of the growth inhibition ring was measured.
  • both the experimental groups a1 to a10 exhibited excellent growth-inhibiting effects against Streptococcus mutans and Popyromonas gingivalis compared to the untreated group a, especially eugenol, saccharin, fluorine, calcium carbonate, or silica, respectively.
  • the growth inhibition effect was all excellent, especially in the experimental group a10 treated with all the active ingredients.
  • PGE2 prostaglandin E2
  • DMEM Dulbecco's Modified Eagle's Medium
  • FBS fetal bovine serum
  • a control toothpaste was made using ingredients that can be generally used to prepare a toothpaste, and an example toothpaste containing each substance was prepared therein.
  • test subjects were gingival inflammatory patients who had even dentition and no missing teeth. 30 subjects were selected from 30 to 50 years of age, followed by precise oral checkups by 30 people according to gender. A clinical trial was conducted on the treatment effect of gingivitis.
  • the experimental group was divided into the experimental group and the control group, and was educated to use 3 times a day before going to sleep after 2 hours after eating, and scored the initial gingivitis index by performing a face wash, and used each toothpaste composition for 1 week, 1 month, 3 After months and 6 months, oral examinations were conducted to examine the gingivitis index.
  • the method of measuring the gingivitis index is by inserting a periodontal probe into the gingival fissure, burning the probe around each tooth without applying force, and measuring the bleeding condition after 30 seconds. Recorded to obtain results.
  • Experiment group c10 0 weeks 1.05 1.04 1.05 1.04 1.06 1.05 1.05 1.04 1.05 1.06 1 week 1.60 1.15 1.45 1.41 1.35 1.40 1.11 1.11 1.10 1.12 1.08 1 month 2.63 1.17 2.00 1.18 2.01 2.10 1.15 1.15 1.15 1.16 1.10 3 months 2.79 1.19 2.35 2.25 2.18 2.32 1.18 1.19 1.17 1.17 1.12 6 months 2.87 1.23 2.52 2.48 2.39 2.40 1.21 1.19 1.20 1.21 1.15
  • the gingivitis index increased with exacerbation of gingival inflammation in the control group, while in the experimental groups c5 to c10 containing eugenol in saccharin, fluorine, calcium carbonate, silica, or a mixture thereof, both the control group, as well as eugenol, saccharin, fluorine, Compared to the calcium carbonate or silica treatment alone (experimental groups c1 to c5), the gingival index was lowered, thereby exhibiting excellent gingivitis improvement effect. In particular, in experimental group c10 containing all of eugenol, saccharin, fluorine, calcium carbonate, and silica It was confirmed that the degree of gingivitis index increase was the lowest, and the effect was also excellent after 6 months.
  • control and experimental group (Example) composition prepared above was compared to the degree of inhibition of the syringe. (See Table 3)
  • the test was conducted by measuring the patient's response after applying temperature stimulation. Before conducting the test, the hypersensitivity area of each candidate's perceptive hypersensitivity teeth was checked beforehand, and each composition was used 3 times a day for 2 weeks after dropping the cold water of about 5°C into the dropper of the tooth with a dropper for evaluation. After 2 weeks, the water was dropped again to a dropper of about 5°C with a dropper for evaluation. After stimulation, the criteria for the patient's response rating were set as follows. (0 point: no discomfort, 1 point: slightly uncomfortable or cold, 3 point: sick). Statistical treatment was tested by paired student-t test for stimulation scores before and 2 weeks after laboratory.
  • Experiment group c10 0 weeks 2.15 ⁇ 0.11 2.14 ⁇ 0.10 2.14 ⁇ 0.09 2.13 ⁇ 0.05 2.14 ⁇ 0.04 2.15 ⁇ 0.11 2.15 ⁇ 0.08 2.14 ⁇ 0.11 2.15 ⁇ 0.01 2.14 ⁇ 0.07 2.13 ⁇ 0.10 2 weeks 2.14 ⁇ 0.10 1.85 ⁇ 0.18 1.90 ⁇ 0.11 1.86 ⁇ 0.08 1.91 ⁇ 0.12 1.89 ⁇ 0.05 1.77 ⁇ 0.20 1.75 ⁇ 0.07 1.80 ⁇ 0.11 1.74 ⁇ 0.08 1.65 ⁇ 0.12 valence p>0.05 *p ⁇ 0.05 *p ⁇ 0.05 *p ⁇ 0.05 *p ⁇ 0.05 *p ⁇ 0.05 *p ⁇ 0.05 *p ⁇ 0.05 *p ⁇ 0.05 *p ⁇ 0.05 *p ⁇ 0.05 *p ⁇ 0.05 *p ⁇ 0.05 *p ⁇ 0.05 *p ⁇ 0.05 *p ⁇ 0.05 *p ⁇ 0.05 *p ⁇ 0.05 *p ⁇ 0.05 *p ⁇ 0.05 *p ⁇ 0.05 *p ⁇ 0.05 *p ⁇ 0.05 *p ⁇ 0.05 *p ⁇ 0.05 *p ⁇ 0.05 *p ⁇ 0.05 *p ⁇ 0.05 *p ⁇ 0.05 *p ⁇ 0.05 *p ⁇ 0.05 *p ⁇ 0.05 *p ⁇
  • the control group had a decrease in index of only 0.01 points compared to the 0-week index, whereas all of the experimental groups c5 to c10 containing eugenol in saccharin, fluorine, calcium carbonate, silica, or mixtures thereof, as well as the control group, eugenol, saccharin, and fluorine , Compared to calcium carbonate or silica alone (experimental groups c1 to c5), superior syrin showed an improvement effect, and in particular, syrin decreased index in experimental group c10 containing all of eugenol, saccharin, fluorine, calcium carbonate, and silica. Was confirmed to be the highest.
  • the present invention is excellent as an antibacterial effect, bad breath, toothache, stomatitis, gingivitis, periodontitis, syringitis, dental caries, periodontal disease, ulcer disease and apical diseases, excellent effect in preventing, improving and treating it is useful as an oral hygiene composition Can be used.

Abstract

The present invention relates to an oral hygiene composition comprising, as active ingredients, eugenol and any one or more selected from the group consisting of saccharin, fluorine, calcium carbonate, and silica. The composition exhibits an excellent antibacterial effect and excellent effects on the prevention, alleviation, and treatment of bad breath, toothache, stomatitis, gingivitis, periodontitis, sensitive teeth, dental caries, periodontal disease, pulpal disease, and periapical disease, and thus can be applied to prevent and treat various oral diseases.

Description

구강 위생 조성물Oral hygiene composition
본 발명은 구취, 치통, 구내염, 치은염, 치주염, 시린이, 치아 우식증, 치주질환, 치수 질환 및 치근단 질환에 우수한 예방 및 치료 효과를 갖는 구강 위생 조성물에 관한 것이다.The present invention relates to an oral hygiene composition having excellent preventive and therapeutic effects on bad breath, toothache, stomatitis, gingivitis, periodontitis, syringitis, dental caries, periodontal disease, pulp disease and apical disease.
구강질환 중 치아우식과 치주질환은 통증, 저작기능 장애, 치주조직의 파괴, 구취 및 시린이와 같은 다양한 임상적인 증상을 유발하고 치아상실을 초래하는 주된 요인으로 알려져 있으며 식생활의 변화로 치아우식의 원인요소는 더 증가하고 있는 실정이다.Dental caries and periodontal disease among oral diseases are known as the main factors that cause various clinical symptoms such as pain, chewing dysfunction, periodontal tissue destruction, bad breath and pain, and cause tooth loss. The causative factor is increasing.
치면세균막 내에 서식하면서 치아우식, 치주질환, 구취 및 시린이를 유발하는 구강병원균 증식을 억제하는 방법으로, 이들 세균들에 대한 살균 및 정균작용을 갖는 항생제를 포함한 다양한 종류의 항균제제가 충치, 치주질환, 치수 및 치근단 감염의 억제 및 치료제로써 개발되어 왔다. It is a method of inhibiting the proliferation of oral pathogens that cause dental caries, periodontal disease, bad breath and soreness while inhabiting the periodontal microbial membrane, and various types of antimicrobial agents including antibiotics having bactericidal and bactericidal action against these bacteria are decayed, periodontal disease , It has been developed as a treatment and suppression of pulp and apical infections.
그런데, 항생제는 우리몸에 대한 전신적인 부작용과 함께 구강내 내성균의 출현 및 균교대증을 유발할 수 있기 때문에 장기적인 사용이 곤란하여 단지 치료제로만 이용될 수 있는 단점이 있다. 또한, 구강청정제에 사용되고 있는 항균제제로는 생구이나린, 리스테린, 피록사이드, 클로르헥시딘 등이 있는데, 생구이나린(Sangquinarine)은 구강내에서 세균에 대한 효과가 불분명하고 치주질환시 치료효과에 대해서는 더욱 불분명할 뿐만 아니라 가격도 비싼 단점이 있고, 리스테린(Listerine)은 알코올이 주성분으로 실제 구강내에서는 일시적인 효과를 내지만 약간의 정균작용이 있으나 장기간 사용시 조직에 대해 위해작용도 나타날 수 있는 단점이 있으며, 최근 미백효과를 위해 첨가되고 있는 피록사이드(Peroxide)는 세균에 대한 독작용이 있으나 동시에 인체조직에도 독작용을 나타내어 안전성에 문제가 있을 뿐 아니라 간혹 세균에서 피록사이드에 대한 내성균이 출현하기도 한다. 또한 클로르헥시딘(Chlorhexidine)은 치태형성억제와 더불어 치주질환예방 및 치료제로써 현재까지 알려진 제제 중에서 가장 우수한 것으로 알려져 있으나, 조직에 대한 자극, 조직의 착색 및 변성, 특히 자극적인 맛이 강하고 냄새가 심한 부작용을 나타내는 문제점이 있을 뿐 아니라, 그 외도 균교대증이 유발될 수 있고, 발암성이 있어 임신부의 경우 사용이 제한되는 등 치료나 특히 예방의 목적으로 장기간 사용할 수 없는 단점이 있다.However, antibiotics have the disadvantage that they can be used only as therapeutic agents because they are difficult to use for a long time because they can induce the appearance of mycobacterium-resistant bacteria and alternation of oral bacteria in addition to systemic side effects on the body. In addition, antibacterial agents used in oral cleansing agents include saline guinarine, listerine, pyroxide, chlorhexidine, etc. Saengquinarine has an unclear effect on bacteria in the oral cavity and is more unclear about the treatment effect in periodontal disease. Not only does it have a high price but also has a disadvantage in that it is expensive, and Listerine is a main component of alcohol, which has a temporary effect in the oral cavity, but has some bacteriostatic effects, but also has a disadvantage in that it may have a harmful effect on tissues when used for a long time. Pyroxide (Peroxide), which is being added for the whitening effect, has a poisonous effect on bacteria, but at the same time has a poisonous effect on human tissues, and also has safety problems, and sometimes bacteria resistant to pyroxide appear in bacteria. In addition, chlorhexidine is known to be the best among the formulations known to date as a preventive and therapeutic agent for periodontal disease in addition to inhibition of plaque formation, but it has a strong irritating and odorous side effect. In addition to the problems indicated, there are other disadvantages that can be used for a long period of time for the purpose of treatment or prevention, such as mycosis, which can also cause carcinogenicity, and limited use in pregnant women.
본 발명은 항균 효과가 우수하고, 구취, 치통, 구내염, 치은염, 치주염, 시린이, 치아 우식증, 치주질환, 치수 질환 및 치근단 질환의 예방, 개선 및 치료에 우수한 구강 위생 조성물을 제공하고자 한다.The present invention is to provide an oral hygiene composition excellent in antibacterial effect, excellent in the prevention, improvement and treatment of bad breath, toothache, stomatitis, gingivitis, periodontitis, syringitis, dental caries, periodontal disease, pulp disease and apical disease.
상기 상술한 목적을 달성하기 위하여 본 발명은 사카린, 불소, 탄산칼슘 및 실리카로 이루어진 군에서 선택되는 어느 하나 이상 및 유게놀을 유효성분으로 포함하는 구강 위생 조성물을 제공한다.In order to achieve the above object, the present invention provides an oral hygiene composition comprising any one or more selected from the group consisting of saccharin, fluorine, calcium carbonate and silica and eugenol as an active ingredient.
본 발명의 일 태양에 따르면, 본 발명의 조성물은 구강 질환 예방, 완화 또는 치료용인 것을 특징으로 한다.According to one aspect of the present invention, the composition of the present invention is characterized in that it is for preventing, alleviating or treating oral diseases.
본 발명의 일 태양에 따르면, 상기 구강 질환은 구취, 치통, 구내염, 치은염, 치주염, 시린이, 치아 우식증, 치주질환, 치수 질환 및 치근단 질환으로 이루어진 군에서 선택되는 어느 하나 이상인 것을 특징으로 한다.According to an aspect of the present invention, the oral disease is characterized in that it is at least one selected from the group consisting of bad breath, toothache, stomatitis, gingivitis, periodontitis, acute teeth, dental caries, periodontal disease, pulp disease and apical disease.
본 발명의 일 태양에 따르면, 상기 사카린, 불소, 탄산칼슘 및 실리카로 이루어진 군에서 선택되는 어느 하나 이상은 유게놀과 1 : 0.1 내지 10의 중량비로 혼합되는 것을 특징으로 한다.According to an aspect of the present invention, any one or more selected from the group consisting of the saccharin, fluorine, calcium carbonate, and silica is characterized by being mixed with eugenol in a weight ratio of 1:0.1 to 10.
본 발명의 일 태양에 따르면, 상기 사카린, 불소, 탄산칼슘 및 실리카로 이루어진 군에서 선택되는 어느 하나 이상은 조성물 총 중량 대비 0.001 내지 0.1 중량% 포함되는 것을 특징으로 한다.According to an aspect of the present invention, any one or more selected from the group consisting of the saccharin, fluorine, calcium carbonate and silica is characterized in that it contains 0.001 to 0.1% by weight based on the total weight of the composition.
본 발명의 일 태양에 따르면, 상기 유게놀은 조성물 총 중량 대비 0.001 내지 0.1 중량% 포함되는 것을 특징으로 한다. According to one aspect of the invention, the eugenol is characterized in that it comprises 0.001 to 0.1% by weight based on the total weight of the composition.
본 발명의 일 태양에 따르면, 상기 조성물은 스트렙토코커스(Streptococcus) 속 또는 포피로모나스(Porphyromonas) 속에 항균 효과가 있는 것을 특징으로 한다.According to one aspect of the invention, the composition is characterized in that it has an antibacterial effect in the genus Streptococcus (Streptococcus) or in Porphyromonas (Porphyromonas).
상기 스트렙토코커스(Streptococcus) 속 또는 포피로모나스(Porphyromonas) 속은 스트렙토코커스 뮤탄스(Streptococcus mutans), 스트렙토코커스 상귀스(Streptococcus sanguis), 스트렙토코커스 상귀니스(Streptococcus sanguinis), 스트렙토코커스 살리바리우스 종 써모필스(Streptococcus salivariussubsp. thermophils), 및 포피로모나스 진지발리스(Porphyromonasgingivalis)로 이루어진 군에서 선택된 하나 이상인 것을 특징으로 한다.The Streptococcus genus or Porphyromonas genus Streptococcus mutans, Streptococcus sanguis, Streptococcus sanguinis, Streptococcus sanguinis, Streptococcus salivaus Streptococcus salivariussubsp. thermophils), and one or more selected from the group consisting of Porphyromonas gingivalis.
본 발명의 일 태양에 따르면, 상술한 구강 위생 조성물을 포함하는 구강용 제품을 제공한다.According to one aspect of the present invention, there is provided an oral product comprising the aforementioned oral hygiene composition.
본 발명의 일 태양에 따르면, 본 발명의 구강용 제품은 치약, 가글링 제품, 껌, 구강 스프레이, 구강용 연고, 구강 세정제 및 구강 청정제로 이루어지는 군 중에서 선택되는 것을 특징으로 한다.According to one aspect of the present invention, the oral product of the present invention is characterized by being selected from the group consisting of toothpaste, gargling product, gum, oral spray, oral ointment, mouthwash and mouthwash.
본 발명은 항균 효과가 우수하고, 구취, 치통, 구내염, 치은염, 치주염, 시린이, 치아 우식증, 치주질환, 치수 질환 및 치근단 질환의 예방, 개선 및 치료에 우수한 효과를 발휘한다.The present invention has excellent antibacterial effect, exerts excellent effects on the prevention, improvement and treatment of bad breath, toothache, stomatitis, gingivitis, periodontitis, syringitis, dental caries, periodontal disease, pulp disease and apical disease.
도 1은 본 발명에 따른 조성물의 프로스타글란딘 E2 (PGE2) 억제 효과를 확인한 실험 결과이다.1 is an experimental result confirming the prostaglandin E2 (PGE2) inhibitory effect of the composition according to the present invention.
상기 상술한 목적을 달성하기 위한 본 발명은 특징으로 한다. 이하 도면을 참조하여 본 발명을 구체적으로 설명한다.The present invention for achieving the above object is characterized. Hereinafter, the present invention will be described in detail with reference to the drawings.
본 발명은 사카린(Sacharine), 불소(F), 탄산칼슘(Calcium carbonate, CaC03) 및 실리카(Silica)로 이루어진 군에서 선택되는 어느 하나 이상 및 유게놀(Eugenol)을 유효성분으로 포함하는 구강 위생 조성물을 제공한다.The present invention is oral hygiene containing any one or more selected from the group consisting of saccharin (Sacharine), fluorine (F), calcium carbonate (CaC0 3 ) and silica (Silica) and eugenol (Eugenol) Provided is a composition.
본 발명의 일 태양에 따르면, 본 발명의 조성물은 구강 질환 예방, 완화 또는 치료용인 것을 특징으로 한다.According to one aspect of the present invention, the composition of the present invention is characterized in that it is for preventing, alleviating or treating oral diseases.
본 발명에서 상기 구강질환은 예를 들어, 이에 한정되는 것은 아니지만, 구취, 시린이, 치아 우식증, 치은염, 치주염, 구강 내 점막 궤양 및 치근단 질환 등을 포함하는 포괄적 개념이다.In the present invention, the oral disease is, for example, but is not limited to bad breath, acute teeth, dental caries, gingivitis, periodontitis, mucosal ulcers in the oral cavity, and apical disease.
본 명세서에서 사용된 용어, "예방"은 상기 구강 위생 조성물을 이용하여 질환을 억제 또는 지연시키는 모든 행위를 의미한다. 또한, 본 명세서에서 사용된 용어, "치료"는 상기 구강 위생 조성물을 이용하여 질환의 증세가 완화되거나 완치되는 모든 행위를 의미한다.As used herein, the term "prevention" refers to any act of suppressing or delaying the disease using the oral hygiene composition. In addition, as used herein, the term "treatment" refers to all actions in which symptoms of the disease are alleviated or cured using the oral hygiene composition.
또한, 본 명세서에서 사용된 용어, "완화"는 상기와 같은 구강질환 증상 등이 줄어들거나 누그러지는 것을 의미하며, 개선, 예방, 치료 등을 포함하는 넓은 개념으로 이해될 수 있다.In addition, the term used in the present specification, "relieving" means that the symptoms of oral disease such as the above are reduced or softened, and can be understood as a broad concept including improvement, prevention, and treatment.
또한, 본 명세서에서 사용된 용어, "개선"은 구강질환 등을 치료하여 증상을 원래의 상태에 가깝도록 회복시키는 것을 의미하는 넓은 개념으로 이해될 수 있다.In addition, as used herein, the term "improvement" can be understood as a broad concept that means to recover symptoms close to the original condition by treating oral diseases and the like.
본 발명의 일 태양에 따르면, 상기 구강 질환은 구취, 치통, 구내염, 치은염, 치주염, 시린이, 치아 우식증, 치주 질환, 치수 질환 및 치근단 질환으로 이루어진 군에서 선택되는 어느 하나 이상인 것을 특징으로 한다.According to an aspect of the present invention, the oral disease is characterized in that it is at least one selected from the group consisting of bad breath, toothache, stomatitis, gingivitis, periodontitis, acute teeth, dental caries, periodontal disease, pulp disease and apical disease.
본 명세서에서 사용된 용어, "구취"는 이에 한정되는 것은 아니지만, 후천적인 전신질환에 의해서나 타액중의 단백질, 음식물 찌꺼기 등이 구강 내에서 미생물에 의해 분해되어 생성된 물질이 분해되어 악취를 유발하는 물질을 생성함으로써 발생할 수 있다. 구취를 유발하는 1차 원인인 구강 내 미생물에는 이에 한정되는 것은 아니지만, 스트렙토코커스(Streptococcus) 속, 포피로모나스(Porphyromonas) 속, 악티노마이세스(Actinomyces) 속, 악티노바실러스(Actinobacillus) 속 등이 있을 수 있다.As used herein, the term "halt breath" is not limited to this, but due to acquired systemic disease, protein in saliva, food debris, etc., is decomposed by microorganisms in the oral cavity to decompose, resulting in odor It can be caused by generating substances. The primary cause of bad breath is not limited to microorganisms in the oral cavity, but is not limited to the genus Streptococcus , genus Porphyromonas , Actinomyces genus, Actinobacillus genus, etc. This can be.
본 명세서에서 사용된 용어, "치통"은 치아에 대한 구조 손상으로 인해 일어나는 것이 가장 흔하고, 이때 보통 상아질과 법랑질에 의해 잘 보호되어 있는 치아 신경들은 우식, 치아 균열, 치근 노출 또는 법랑질 침식의 결과뿐만 아니라 치은 질환, 농양 또는 매복 등에 의해 외부 자극에 노출된다.As used herein, the term "toothache" most commonly occurs due to structural damage to the teeth, where dental nerves, which are usually well protected by dentin and enamel, are not only the result of caries, tooth cracking, tooth root exposure or enamel erosion. In addition, it is exposed to external stimuli by gingival diseases, abscesses or ambushes.
본 명세서에서 사용된 용어, "구내염(stomatitis)"은 구강 내 점막 궤양 이라고도 하며, 이에 한정되는 것은 아니지만 구강 내 세균, 바이러스, 곰팡이 등에 의한 감염으로 인해 구강 내 점막(혜, 잇몸, 입술, 볼 안쪽 등)에 염증이 생기는 질환을 의미하며 상기 세균은 스트렙토코커스(Streptococcus) 속, 포피로모나스(Porphyromonas) 속 등의 세균일 수 있다.As used herein, the term “stomatitis” is also referred to as mucosal ulcer in the oral cavity, but is not limited thereto, due to infection by bacteria, viruses, fungi, etc. in the oral cavity (hymen, gums, lips, cheeks inside) Etc.) refers to a disease in which inflammation occurs, and the bacteria may be bacteria such as the genus Streptococcus and the genus Porphyromonas.
본 명세서에서 사용된 용어, "치은염" 및 "치주염"은, 이에 한정되는 것은 아니지만, 치은연하치태내에 존재하는 스트렙토코커스(Streptococcus) 속, 포피로모나스(Porphyromonas) 속 등의 세균이 적절한 생육조건이 형성되었을 때 치은 부위의 연조직에 감염을 일으켜 치은염 또는 치주염의 치주질환으로 발전하여 잇몸의 염증을 일으키는 구강질환일 수 있다.As used herein, the term "gingivitis" and "gingivitis" are not limited to this, but the bacteria, such as the genus Streptococcus, Porphyromonas, which are present in the subgingival plaque, have appropriate growth conditions. When it is formed, it may be an oral disease that causes inflammation of the gums by developing an infection in the soft tissues of the gingival area and developing a periodontal disease of gingivitis or periodontitis.
본 명세서에서 사용된 용어, "시린이"는 이에 한정되는 것은 아니지만, 충치나 다른 병적인 원인과 별개로, 외부 자극에 대해 예리하고 일시적이거나 지속적인 통증이 나타나는 모든 현상을 의미한다. 상기 외부 자극은 보통 온도 자극을 의미하며, 대개 차가운 온도 자극에 증상을 호소하는데 뜨거운 온도에 통증이 나타나기도 한다. 이와 같은 온도 자극 외에도 치아의 건조, 외부 물질과의 접촉, 달거나 신 음식을 통한 삼투압 등의 자극에 의해서도 통증이 나타날 수 있다. 이는 치아 전체에 전반적으로 나타나기도 하며, 상악이나 하악, 또는 오른쪽이나 왼쪽 등 특정 부위에 한정되어 나타나기도 하고, 상아질 지각과민증(dentine hyperesthesia), 우식, 치수 염증과 동반하기도 한다. 이러한 시린이 증상의 원인으로는 상아세관의 입구 노출을 고려할 수 있다. 에나멜질 또는 시멘트질이 파괴되어 상아세관의 입구가 외부로 노출되면 상아세관의 세포돌기, 신경 및 상아질액에 의하여 자극이 치수 쪽으로 전달되어 통증을 느낄 수 있다.As used herein, the term "syrinyi" means, but is not limited to, cavities or other pathological causes, apart from external stimulation, refers to any phenomenon that appears sharp, temporary or persistent pain. The external stimulus usually refers to a temperature stimulus, and usually complains of a symptom in a cold temperature stimulus. In addition to this temperature stimulation, pain may also be caused by stimulation such as drying of the teeth, contact with foreign substances, osmotic pressure through sweet or sour food. It may appear throughout the entire tooth, and may be limited to certain areas, such as the maxilla or mandible, or the right or left side, and may be accompanied by dentin hyperesthesia, caries, and pulp inflammation. As a cause of this symptom, the exposure of the mouth of the ivory tubule may be considered. When enamel or cementite is destroyed and the entrance of the ivory tubules is exposed to the outside, stimulation is transmitted to the pulp by the cell processes, nerves, and dentin fluid of the ivory tubules, and pain can be felt.
본 명세서에서 사용된 용어, "치아우식증"이란 치아의 표면에 부착한 치면 세균막 내의 세균(Streptococcus mutans 등)에 의해 치아의 경조직이 파괴되는 병변으로서, 세균에 의해 생성된 유기산에 의해 치질의 무기질 성분(칼슘염)이 탈회되고, 다시 세균으로부터의 효소에 의해 유기질 성분이 분해되는 것이다. 예를 들어, 치아 표면에 생성된 바이오필름인 플라크(plaque)가 원인일 수 있다. 상기 치아우식증을 일으키는 세균은 스트렙토코커스(Streptococcus) 속, 포피로모나스(Porphyromonas) 속 등일 수 있다.As used herein, the term "tooth caries" refers to a lesion in which the hard tissue of a tooth is destroyed by bacteria (Streptococcus mutans, etc.) in the dental bacterial membrane attached to the surface of the tooth, an inorganic component of hemorrhoids by organic acids produced by bacteria (Calcium salt) is demineralized, and the organic component is decomposed again by enzymes from bacteria. For example, plaque, a biofilm produced on the surface of a tooth, may be the cause. The bacteria that cause dental caries may be of the genus Streptococcus , of the genus Porphyromonas , and the like.
본 명세서에서 사용된 용어, "치주 질환"은 치은염과 치주염으로 구분하며 치은염은 치은에 국한되어 발생한 염증성 병변이고, 치주염은 치은을 포함한 치주인대와 치조골에 발생한 병변이다. 일부에서는 치주질환을 근단성 치주염과 치주질환으로 구분하기도 한다. 그러나 근단성 치주염은 발생하는 위치로 볼 때 용어의 정의는 정확하지만, 임상에서는 치근단 질환으로 부르는 경우가 대부분이다.As used herein, the term “periodontal disease” is divided into gingivitis and periodontitis, and gingivitis is an inflammatory lesion confined to the gingiva, and periodontitis is a lesion occurring on the periodontal ligament and alveolar bone including gingivitis. In some cases, periodontal disease is divided into acute periodontitis and periodontal disease. However, although the term definition is correct in terms of the location where apical periodontitis occurs, it is most often referred to as apical disease in clinical practice.
본 명세서에서 사용된 용어, "치수 질환"은 염증성 병변과 비염증성 병변으로 구분하며, 염증성 병변에는 치수염, 비염증성 병변에는 위축, 변성, 괴사 등의 퇴행성 병변이 있다. 치수는 혈관과 신경이 분포되어 있는 소성 결합조직으로, 주위가 석회화된 상아질로 둘러싸여 있다. 염증 시에는 혈관이 충혈되고 부종으로 인하여 치수조직이 종창되어 치수의 내압이 상승되기 때문에 치수조직이 다른 조직에 비하여 염증이 빨리 진행되고 동통이 심하다.As used herein, the term "dimension disease" is divided into inflammatory lesions and non-inflammatory lesions, and inflammatory lesions include degenerative lesions such as pulpitis, non-inflammatory lesions, atrophy, degeneration, and necrosis. The pulp is a plastic connective tissue with blood vessels and nerves distributed around it, surrounded by calcified dentin. During inflammation, blood vessels become congested and pulp tissue swells due to edema, which increases the internal pressure of the pulp, so inflammation of the pulp tissue progresses faster and pain is worse than other tissues.
본 명세서에서 사용된 용어, "치근단 질환"은 치근단 주위의 치주조직에서 나타나는 염증성 병변으로서, 개방성 치수염, 치수괴사 또는 치수괴저, 근관처치가 불충분한 경우, 낮은 독성의 박테리아가 있는 경우에 발생한다.As used herein, the term "apical disease" is an inflammatory lesion occurring in the periodontal tissue around the apical tip, which occurs when there is insufficient open-mouth pulpitis, pulp necrosis or pulp gangrene, root canal treatment, or low toxicity bacteria.
본 발명의 일 태양에 따르면, 본 발명의 구강 위생 조성물은 사카린, 불소, 탄산칼슘 및 실리카로 이루어진 군에서 선택되는 어느 하나 이상은 유게놀과 1 : 0.1 내지 10의 중량비, 구체적으로 1 : 0.5 내지 5의 중량비, 더욱 구체적으로 1 : 0.3 내지 3의 중량비, 가장 구체적으로는 1:1의 중량비로 포함될 수 있다.According to one aspect of the present invention, the oral hygiene composition of the present invention is any one or more selected from the group consisting of saccharin, fluorine, calcium carbonate, and silica eugenol and a weight ratio of 1: 0.1 to 10, specifically 1: 0.5 to It may be included in a weight ratio of 5, more specifically 1: a weight ratio of 0.3 to 3, and most specifically, a weight ratio of 1:1.
본 발명의 일 태양에 따르면, 사카린, 불소, 탄산칼슘 및 실리카로 이루어진 군에서 선택되는 어느 하나 이상은 조성물 총 중량 대비 0.001 내지 0.1 중량%, 구체적으로 0.001 내지 0.05중량%, 더욱 구체적으로 0.005 내지 0.01 중량%로 포함될 수 있다.According to an aspect of the present invention, any one or more selected from the group consisting of saccharin, fluorine, calcium carbonate and silica is 0.001 to 0.1% by weight, specifically 0.001 to 0.05% by weight, more specifically 0.005 to 0.01, based on the total weight of the composition It may be included in weight percent.
본 발명의 일 태양에 따르면, 사카린, 불소, 탄산칼슘 및 실리카로 이루어진 군에서 선택된 어느 두 성분 이상이 본 발명의 조성물에 포함되는 경우 임의의 어느 한 성분 대비하여 나머지 성분의 비율이 1 : 0.1 내지 10의 중량비, 구체적으로 1 : 0.1 내지 5의 중량비, 더 구체적으로 1 : 0.5 내지 3의 중량비로 포함될 수 있다. According to an aspect of the present invention, when any two or more components selected from the group consisting of saccharin, fluorine, calcium carbonate, and silica are included in the composition of the present invention, the ratio of the remaining components compared to any one component is 1:0.1 to It may be included in a weight ratio of 10, specifically 1: 0.1 to 5, and more specifically 1: 0.5 to 3.
본 발명의 일 태양에 따르면, 유게놀은 조성물 총 중량 대비 0.001 내지 0.05 중량%, 구체적으로 0.001 내지 0.05중량%, 더욱 구체적으로 0.005 내지 0.01 중량%로 포함될 수 있다.According to an aspect of the present invention, eugenol may be included in an amount of 0.001 to 0.05% by weight, specifically 0.001 to 0.05% by weight, and more specifically 0.005 to 0.01% by weight based on the total weight of the composition.
본 발명의 일 태양에 따르면, 사카린, 불소, 탄산칼슘 및 실리카로 이루어진 군에서 선택된 어느 하나 이상 및 유게놀이 본 발명의 조성물에 포함되는 경우 사카린, 불소, 탄산칼슘 및 실리카로 이루어진 군에서 선택된 어느 하나 이상 대비하여 유게놀의 비율이 1 : 0.1 내지 10의 중량비, 구체적으로 1 : 0.1 내지 5의 중량비, 더 구체적으로 1 : 0.5 내지 3의 중량비로 포함될 수 있다. According to an aspect of the present invention, any one or more selected from the group consisting of saccharin, fluorine, calcium carbonate and silica and eugenol when included in the composition of the present invention, any one selected from the group consisting of saccharin, fluorine, calcium carbonate and silica In contrast to the above, the ratio of eugenol may be included in a weight ratio of 1:0.1 to 10, specifically 1:0.1 to 5, and more specifically 1:0.5 to 3.
본 발명의 일 태양에 따르면, 본 발명의 구강 위생 조성물은 스트렙토코커스(Streptococcus) 속 또는 포피로모나스(Porphyromonas) 속에 항균 효과가 우수하여 구강질환의 예방 및 치료에 우수한 효과가 있음을 확인하였다.According to one aspect of the present invention, it was confirmed that the oral hygiene composition of the present invention has an excellent antibacterial effect in Streptococcus or Porphyromonas and has excellent effects in preventing and treating oral diseases.
본 발명의 구강 위생 조성물은 스트렙토코커스(Streptococcus) 속 또는 포피로모나스(Porphyromonas) 속은 스트렙토코커스 뮤탄스(Streptococcus mutans), 스트렙토코커스 상귀스(Streptococcus sanguis), 스트렙토코커스 상귀니스(Streptococcus sanguinis), 스트렙토코커스 살리바리우스 종 써모필스(Streptococcus salivariussubsp. thermophils), 및 포피로모나스 진지발리스(Porphyromonasgingivalis)로 이루어진 군에서 선택된 하나 이상에 항균 효과를 발휘할 수 있다.The oral hygiene composition of the present invention includes Streptococcus or Streptococcus mutans, Streptococcus sanguis, Streptococcus sanguinis, Streptococcus sanguinis, Streptococcus sanguinis It can exert an antibacterial effect on one or more selected from the group consisting of Streptococcus salivariussubsp. thermophils, and Porphyromonasgingivalis.
본 발명의 구강 위생 조성물은 상술한 성분 이외에, 그 제형 및 사용 목적에 따라 통상적으로 성분들로서, 습윤제, 연마제, 약효제, 감미제, pH조정제, 방부제, 결합제, 향료, 기포제 등을 더 포함할 수 있다. Oral hygiene composition of the present invention, in addition to the above-mentioned components, as a component in general according to the formulation and purpose of use, we may further include a wetting agent, abrasives, agonists, sweeteners, pH adjusting agents, preservatives, binders, flavoring agents, foaming agents and the like. .
습윤제로는 농글리세린, 글리세린, 소르비톨수용액, 비결정성 소르비톨수용액, 폴리에틸렌글리콜류 및 프로필렌글리콜로 이루어진 군중에서 단독 또는 혼합하여 사용하며, 그 사용량은 구강 위생 조성물 전체 중량 대비 1 내지 70중량% 포함될 수 있다.Wetting agents are used alone or in a mixture of concentrated glycerin, glycerin, sorbitol aqueous solution, amorphous sorbitol aqueous solution, polyethylene glycols, and propylene glycol, and the amount used may be 1 to 70% by weight based on the total weight of the oral hygiene composition .
연마제로는 침강실리카, 실리카겔, 지르코늄실리케이트, 인산일수소칼슘, 무수인산일수소칼슘, 함수알루미나, 경질탄산칼슘, 중질탄산칼슘, 칼슘피로인산염, 불용성메타인산염 및 알루미늄실리케이트로 이루어진 군중에서 선택된 1종 등을 사용할 수 있다. 이러한 연마제의 사용량은 일반적으로 구강 위생 조성물 총 중량 대비 1 내지 60 중량%일 수 있다. 또한 소량 사용되는 첨가제로는 통상 사용되는 성분들로서 감미제, pH 조정제, 방부제, 착색제, 결합제가 포함될 수 있다. The abrasive is selected from the group consisting of precipitated silica, silica gel, zirconium silicate, calcium monohydrogen phosphate, calcium monohydrogen phosphate, hydrous alumina, light calcium carbonate, heavy calcium carbonate, calcium pyrophosphate, insoluble metaphosphate, and aluminum silicate. Etc. can be used. The amount of the abrasive may be generally 1 to 60% by weight based on the total weight of the oral hygiene composition. In addition, additives used in a small amount may include sweeteners, pH adjusters, preservatives, colorants, and binders as commonly used components.
약효제는 불화나트륨, 일불소인산나트륨, 불화나트륨, 불화주석, 클로로헥시딘, 알란토인 클로로히드록시알루미네이트, 아미노카프론산, 염화아연, 염산피리독신, 초산토코페롤, 효소류 등을 단독 또는 2종 이상 혼합하여 사용할 수 있다. Sodium fluoride, sodium monofluorophosphate, sodium fluoride, tin fluoride, chlorohexidine, allantoin chlorohydroxyaluminate, aminocaproic acid, zinc chloride, pyridoxine hydrochloride, tocopherol acetate, enzymes, etc. It can be used by mixing above.
결합제로는 카르복시메틸셀룰로오스나트륨, 카보머, 카라기난, 잔탄검, 알지네이트류 등을 사용할 수 있고, 기포제로서 알킬황산나트륨, 라우릴황산나트륨, 자당지방산에스테르, 소르비탄지방산에스테르 등의 음이온 및 비이온 계면 활성제를 단독 또는 2종 이상을 혼합하여 사용할 수 있다. 이러한 결합제의 사용량은 일반적으로 구강 위생 조성물 총 중량 대비 0.1 내지 3 중량%이며, 바람직하게 0.5 내지 2 중량%일 수 있다.As the binder, sodium carboxymethylcellulose, carbomer, carrageenan, xanthan gum, alginate, and the like can be used. As the foaming agent, anionic and nonionic surfactants such as sodium alkylsulfate, sodium lauryl sulfate, sucrose fatty acid ester, and sorbitan fatty acid ester can be used. It can be used alone or in combination of two or more. The amount of the binder used is generally 0.1 to 3% by weight based on the total weight of the oral hygiene composition, and may preferably be 0.5 to 2% by weight.
감미제로는 사카린, 자일리톨, 에리스리톨, 아스파탐 등을 사용할 수 있으며, 이러한 감미제의 사용량은 일반적으로 구강 위생 조성물 총 중량 대비 0.05 내지 2 중량%일 수 있다.Saccharin, xylitol, erythritol, aspartame, etc. may be used as the sweetener, and the amount of the sweetener may be 0.05 to 2% by weight based on the total weight of the oral hygiene composition.
pH조정제로는 인산나트륨, 인산이나트륨, 구연산, 트리에탄올아민 등을 사용할 수 있다.As the pH adjusting agent, sodium phosphate, disodium phosphate, citric acid, triethanolamine, and the like can be used.
방부제로는 안식향산, 메틸파라벤, 프로필파라벤, 안식향산나트륨 등을 사용할 수 있다. 향료로는 페퍼민트 오일, 스피아민트 오일, 멘톨 등을 혼합하여 사용하기도 하며, 기타 첨가제로서 덱스타라나제 등의 효소류를 사용 할 수도 있다.As a preservative, benzoic acid, methylparaben, propylparaben, sodium benzoate, etc. may be used. As a fragrance, peppermint oil, spearmint oil, and menthol may be used in combination, and enzymes such as dextranase may be used as other additives.
기포제로는 음이온성 계면활성제인 라우릴황산나트륨, 비이온성 계면활성제인 폴리옥시에틸렌폴리옥시프로필렌의 공중합체(폴록사머), 폴리옥시에틸렌경화피마자유, 폴리옥시에틸렌솔비탄 지방산에스테르 등이 사용될 수 있다. 이러한 기포제의 사용량은 일반적으로 구강 위생 조성물 총 중량 대비 0.5 내지 5 중량%이며, 바람직하게 0.5 내지 3.5 중량%일 수 있다.As the foaming agent, anionic surfactant sodium lauryl sulfate, copolymer of nonionic surfactant polyoxyethylene polyoxypropylene (poloxamer), polyoxyethylene cured castor oil, polyoxyethylene sorbitan fatty acid ester, etc. may be used. . The amount of the foaming agent is generally 0.5 to 5% by weight based on the total weight of the oral hygiene composition, preferably 0.5 to 3.5% by weight.
그밖에 잔량의 물을 포함한다.In addition, it contains the remaining amount of water.
본 발명은 사카린, 불소, 탄산칼슘 및 실리카로 이루어진 군에서 선택되는 어느 하나 이상 및 유게놀을 유효 성분으로 포함하는 구강 질환 예방 또는 개선용 구강 위생 조성물을 제공하고, 이는 구강의 위생을 위하여 사용할 수 있는 모든 종류 및 제형을 포함한다. 따라서 상기 구강 위생 조성물의 비제한적인 예로는, 식품 조성물 및 약학 조성물(의약외품 조성물 포함)을 포함하고, 구체적으로, 치약, 구강 세정제, 구강용 스프레이, 구강용 연고제, 검 등을 들 수 있다.The present invention provides an oral hygiene composition for preventing or improving oral diseases comprising eugenol and any one or more selected from the group consisting of saccharin, fluorine, calcium carbonate and silica, which can be used for oral hygiene. Includes all types and formulations. Therefore, non-limiting examples of the oral hygiene composition include a food composition and a pharmaceutical composition (including quasi-drug composition), specifically, toothpaste, mouthwash, oral spray, oral ointment, gum, and the like.
본 발명의 일 태양에 따르면, 사카린, 불소, 탄산칼슘 및 실리카로 이루어진 군에서 선택되는 어느 하나 이상 및 유게놀을 유효 성분으로 포함하는 구강 질환 예방 또는 개선용 식품 조성물을 제공한다. 본 발명의 식품 조성물의 예로는 식품, 식품첨가제, 음료 또는 음료첨가제를 들 수 있다.According to an aspect of the present invention, there is provided a food composition for preventing or improving oral diseases comprising at least one selected from the group consisting of saccharin, fluorine, calcium carbonate, and silica and eugenol as an active ingredient. Examples of the food composition of the present invention include food, food additives, beverages or beverage additives.
본 발명의 식품 조성물은 구취, 치통, 구내염, 치은염, 치주염, 시린이, 치아 우식증, 치주질환, 치수 질환 및 치근단 질환으로 이루어진 군에서 선택되는 어느 하나 이상의 구강 질환에 대하여 예방 및 개선 효과를 발휘할 수 있다.The food composition of the present invention can exert a preventive and improving effect on any one or more oral diseases selected from the group consisting of bad breath, toothache, stomatitis, gingivitis, periodontitis, sirin, dental caries, periodontal disease, pulp disease and apical disease have.
본 발명의 일 태양에 따르면, 사카린, 불소, 탄산칼슘 및 실리카로 이루어진 군에서 선택되는 어느 하나 이상 및 유게놀을 유효 성분으로 포함하는 구강 질환의 예방, 개선 또는 치료용 약학 조성물을 제공한다.According to an aspect of the present invention, there is provided a pharmaceutical composition for the prevention, improvement or treatment of oral diseases comprising at least one selected from the group consisting of saccharin, fluorine, calcium carbonate and silica and eugenol as an active ingredient.
본 발명의 약학 조성물은 구취, 치통, 구내염, 치은염, 치주염, 시린이, 치아 우식증, 치주질환, 치수 질환 및 치근단 질환으로 이루어진 군에서 선택되는 어느 하나 이상의 구강 질환에 대하여 예방, 개선 및 치료 효과를 발휘할 수 있다.The pharmaceutical composition of the present invention prevents, improves and treats at least one oral disease selected from the group consisting of bad breath, toothache, stomatitis, gingivitis, periodontitis, syringitis, dental caries, periodontal disease, pulp disease and apical disease Can be exercised.
본 발명의 일 태양에 따르면, 상술한 구강 위생 조성물을 포함하는 구강용 제품을 제공한다. According to one aspect of the present invention, there is provided an oral product comprising the aforementioned oral hygiene composition.
본 발명에 따른 구강 위생 조성물은 일반적으로 구강 건강을 위해 제조, 시판되는 제품들에 모두 포함될 수 있는 구강 위생 조성물로서, 적용되는 구강용 제품에는 제한이 없다. 본 발명의 일 태양에 따르면, 본 발명의 구강용 제품은 치약, 가글링 제품, 껌, 구강 스프레이, 구강용 연고, 구강 세정제 및 구강 청정제로 이루어지는 군 중에서 선택되는 것을 특징으로 한다.The oral hygiene composition according to the present invention is an oral hygiene composition that can be generally included in products manufactured and marketed for oral health, and there is no limitation on the applied oral products. According to one aspect of the present invention, the oral product of the present invention is characterized by being selected from the group consisting of toothpaste, gargling product, gum, oral spray, oral ointment, mouthwash and mouthwash.
이하, 실시 예를 통해서 본 발명을 보다 상세히 설명하기로 한다. 하지만, 이들은 본 발명을 보다 상세하게 설명하기 위한 것일 뿐 본 발명의 권리범위가 이에 한정되는 것은 아니다.Hereinafter, the present invention will be described in more detail through examples. However, these are only for explaining the present invention in more detail, and the scope of the present invention is not limited thereto.
[실시예 1] 항균효과 실험[Example 1] Antibacterial effect experiment
치아 우식과 치주 질환 대표유발 세균인, 그람양성균 스트렙토코커스 뮤탄스(Streptococcus mutans)와 그람음성균인 포피로모나스 진지발리스(Porphyromonas gingivalis)를 이용하여 균주를 억제하는 효과가 있는지 페이퍼 디스크 검사법을 사용하여 항균력 테스트를 실시하였다. The paper disk test method is used to determine whether it has the effect of inhibiting strains using Gram-positive bacteria Streptococcus mutans and Gram-negative bacteria Porphyromonas gingivalis , which are representative caries and dental periodontal bacteria. Antibacterial activity test was conducted.
상기 각 세균들은 하기 표 1의 최적 배양조건에서 활성을 키운 후, 각 균의 최적배지에서 4~6시간 정도 배양하여 배양액의 탁도를 Macfarland turbidity No. 0.5 (1.5x108)가 되도록 맞춘 후, 0.1㎖를 골고루 도말하였다. 멸균한 페이퍼 디스크(Whatman no.5 paper, 8mm diameter)에 각각의 물질들의 처리 농도 총합이 10mg/disc 농도로 접종하여 1시간 동안 흡수 건조시킨 뒤 사용하였다. 상기의 각 세균의 최적온도에서 24-48시간 배양 후 생육저지환의 크기(직경 mm)를 측정하였다.Each of the above bacteria, after cultivating activity under the optimum culture conditions in Table 1, was cultured for 4 to 6 hours in the optimum medium of each bacterium to increase the turbidity of the culture medium in Macfarland turbidity No. After adjusting to 0.5 (1.5x10 8 ), 0.1 ml was spread evenly. After sterilizing paper disks (Whatman no.5 paper, 8mm diameter), the total concentration of treatment of each material was inoculated at a concentration of 10mg/disc and absorbed and dried for 1 hour. After culturing 24-48 hours at the optimum temperature of each bacterium, the size (diameter mm) of the growth inhibition ring was measured.
균주Strain 최적조건Optimal condition
그람염색 (Gram staining)Gram staining 균주명Strain name 온도Temperature 배지badge 형질characteristics
Gram (+)Gram (+) Streptococcus mutansStreptococcus mutans 37℃37℃ BHIBHI Facultative anaerobicFacultative anaerobic
Gram (-)Gram (-) Porphyromonas gingivalisPorphyromonas gingivalis 37℃37℃ TSA Hemin Menadione mediumTSA Hemin Menadione medium AnaerobicAnaerobic
그 결과는 하기 표와 같다.The results are shown in the table below.
구분division 처리 물질 (농도)Treatment material (concentration) 생육저지환 직경 (mm)Growth inhibition diameter (mm)
S.mutansS.mutans P. gingivalisP. gingivalis
무처리군aUntreated group a 무처리No treatment - (No inhibition)-(No inhibition) - (No inhibition)-(No inhibition)
실험군a1Experiment group a1 유게놀(10mg/disc)Eugenol (10 mg/disc) 9.09.0 9.39.3
실험군a2Experiment group a2 사카린(10mg/disc)Saccharin (10mg/disc) 8.18.1 8.28.2
실험군a3Experiment group a3 불소(10mg/disc)Fluorine (10mg/disc) 8.08.0 8.08.0
실험군a4Experiment group a4 탄산칼슘(10mg/disc)Calcium carbonate (10mg/disc) 8.88.8 8.58.5
실험군a5Experiment group a5 실리카(10mg/disc)Silica (10mg/disc) 8.48.4 8.68.6
실험군a6Experiment group a6 유게놀+사카린(5mg/disc+5mg/disc)Eugenol + Saccharin (5mg/disc+5mg/disc) 9.89.8 10.010.0
실험군a7Experiment group a7 유게놀+불소(5mg/disc+5mg/disc)Eugenol + Fluorine (5mg/disc+5mg/disc) 9.79.7 9.99.9
실험군a8Experiment group a8 유게놀+탄산칼슘(5mg/disc+5mg/disc)Eugenol + calcium carbonate (5mg/disc+5mg/disc) 9.99.9 9.99.9
실험군a9Experiment group a9 유게놀+실리카(5mg/disc+5mg/disc)Eugenol+silica (5mg/disc+5mg/disc) 9.79.7 10.110.1
실험군a10Experiment group a10 유게놀+사카린+불소+탄산칼슘+실리카(2mg/disc+2mg/disc+2mg/disc+2mg/disc+2mg/disc)Eugenol + Saccharin + Fluorine + Calcium Carbonate + Silica (2mg/disc+2mg/disc+2mg/disc+2mg/disc+2mg/disc) 12.012.0 12.112.1
실험 결과, 실험군 a1 내지 a10 모두 무처리군a에 비하여 스트렙토코커스 뮤탄스 및 포피로모나스 진지발리스에 대하여 우수한 생육 저지 효과를 발휘하였고, 특히 유게놀, 사카린, 불소, 탄산칼슘 또는 실리카를 각각 단독처리한 경우(실험군 a1 내지 a5) 보다 어느 하나 이상을 조합처리한 경우(실험군 a6 내지 a10) 생육 저지 효과가 모두 우수하였으며, 특히 상기 유효 성분을 모두 처리한 실험군 a10에서 가장 우수한 생육 저지 효과를 발휘하였다. As a result of the experiment, both the experimental groups a1 to a10 exhibited excellent growth-inhibiting effects against Streptococcus mutans and Popyromonas gingivalis compared to the untreated group a, especially eugenol, saccharin, fluorine, calcium carbonate, or silica, respectively. When treated with any one or more combinations (experimental groups a1 to a5) than the treated group (experimental groups a1 to a5), the growth inhibition effect was all excellent, especially in the experimental group a10 treated with all the active ingredients. Did.
[실시예 2] 프로스타글란딘 E2 (PGE2) 억제 효과[Example 2] Prostaglandin E2 (PGE2) inhibitory effect
치통 완화 효과를 확인하기 위해, 통증 및 염증 마커인 프로스타글란딘 E2 (PGE2) 억제효능을 확인해 보았다. 대식세포를 10% 우태아혈청(FBS)를 포함하는 둘베코즈 수정이글 배지(DMEM)에서 1.5x105 cells/ml 농도로 접종하여 37℃, 5% CO2 조건으로 24 well 플레이트에 24시간을 배양하였다. 그리고 염증 유도 자극원인 LPS(lipopolysaccharide) 1㎍/ml와 각각의 물질들을 다음 표와 같이 처리하여 24시간 배양한 상층액으로 PGE2 억제능을 평가하였다. To confirm the effect of alleviating toothache, the inhibitory effect of prostaglandin E2 (PGE2), a pain and inflammation marker, was confirmed. Macrophages were inoculated at a concentration of 1.5x10 5 cells/ml in Dulbecco's Modified Eagle's Medium (DMEM) containing 10% fetal bovine serum (FBS), and cultured for 24 hours in a 24 well plate at 37°C and 5% CO 2 conditions. Did. In addition, 1 μg/ml of LPS (lipopolysaccharide), which is an inflammation-inducing stimulator, and each substance were treated as shown in the following table to evaluate PGE2 inhibitory ability with supernatant cultured for 24 hours.
구분 division 처리 물질 (농도) Treatment material (concentration)
무처리군bUntreated group b 무처리 No treatment
LPS군LPS group LPS (1㎍/ml)LPS (1 μg/ml)
실험군b1Experiment group b1 유게놀(100ppm)Eugenol (100 ppm)
실험군b2Experiment group b2 사카린(100ppm)Saccharin (100ppm)
실험군b3Experiment group b3 불소(100ppm)Fluorine (100ppm)
실험군b4Experiment group b4 탄산칼슘(100ppm)Calcium carbonate (100ppm)
실험군b5Experiment group b5 실리카(100ppm)Silica (100ppm)
실험군b6Experiment group b6 유게놀+사카린 (50ppm+50ppm)Eugenol + Saccharin (50ppm+50ppm)
실험군b7Experiment group b7 유게놀+불소 (50ppm+50ppm)Eugenol + Fluorine (50ppm+50ppm)
실험군b8Experiment group b8 유게놀+탄산칼슘 (50ppm+50ppm)Eugenol + calcium carbonate (50ppm+50ppm)
실험군b9Experiment group b9 유게놀+실리카 (50ppm+50ppm)Eugenol+silica (50ppm+50ppm)
실험군b10Experiment group b10 유게놀+사카린+불소+탄산칼슘+실리카(20ppm+20ppm+20ppm+20ppm+20ppm)Eugenol + Saccharin + Fluorine + Calcium Carbonate + Silica (20ppm+20ppm+20ppm+20ppm+20ppm)
실험 결과는 도 1에 나타내었다. 사카린, 불소, 탄산칼슘, 실리카 또는 이들의 혼합물에 유게놀을 포함하는 실험군 b5 내지 b10 모두 무처리군b는 물론 유게놀, 사카린, 불소, 탄산칼슘 또는 실리카 각각 단독처리한 경우(실험군 b1 내지 b5)에 비하여 우수한 프로스타글란딘 억제 효과를 발휘하였고, 특히 유게놀, 사카린, 불소, 탄산칼슘 및 실리카를 모두 포함하는 실험군 b10에서 가장 우수한 생육 저지 효과를 발휘하였다. The experimental results are shown in FIG. 1. In the experimental groups b5 to b10 containing eugenol in saccharin, fluorine, calcium carbonate, silica, or mixtures thereof, both untreated group b, as well as eugenol, saccharin, fluorine, calcium carbonate, or silica, respectively (experimental groups b1 to b5) ), it showed excellent prostaglandin inhibitory effect, and particularly, it showed the best growth inhibition effect in experimental group b10 including all of eugenol, saccharin, fluorine, calcium carbonate, and silica.
[실시예 3] 치은 염증 형성 억제효과[Example 3] Gingivitis inflammation inhibitory effect
치은 염증 형성 억제 정도를 비교하기 위하여, 치약을 제조하기 위해 일반적으로 사용될 수 있는 성분들을 사용하여 대조군 치약을 만들었고, 여기에 각각의 물질을 함유한 실시예 치약을 제조하였다.In order to compare the degree of inhibition of gingival inflammation formation, a control toothpaste was made using ingredients that can be generally used to prepare a toothpaste, and an example toothpaste containing each substance was prepared therein.
대조군Control 카르복시메칠세룰로오스나트륨, 라우릴황산나트륨, 글리세린, 콜리이드성 이산화규소, 실리카류, 소디움코코일이세치온산나트륨, 도디신과 감미제, 방향제, 착색제Sodium carboxymethylcellulose, sodium lauryl sulfate, glycerin, colloidal silicon dioxide, silicas, sodium cocoyl isethionate, dodecine and sweetener, fragrance, colorant
실험군c1Experiment group c1 대조군 + 유게놀 0.01%Control + Eugenol 0.01%
실험군c2Experiment group c2 대조군 + 사카린 0.01%Control group + saccharin 0.01%
실험군c3Experiment group c3 대조군 + 불소 0.01%Control + Fluorine 0.01%
실험군c4Experimental group c4 대조군 + 탄산칼슘 0.01%Control group + calcium carbonate 0.01%
실험군c5Experiment group c5 대조군 + 실리카 0.01%Control + silica 0.01%
실험군c6Experiment group c6 대조군 + 유게놀 0.005% + 사카린 0.005%Control group + eugenol 0.005% + saccharin 0.005%
실험군c7Experiment group c7 대조군 + 유게놀 0.005% + 불소 0.005%Control + Eugenol 0.005% + Fluorine 0.005%
실험군c8Experiment group c8 대조군 + 유게놀 0.005% + 탄산칼슘 0.005%Control group + eugenol 0.005% + calcium carbonate 0.005%
실험군c9Experiment group c9 대조군 + 유게놀 0.005% + 실리카 0.005%Control + Eugenol 0.005% + Silica 0.005%
실험군c10Experiment group c10 대조군 + 유게놀 0.002% + 사카린 0.002% + 불소 0.002% + 탄산칼슘 0.002% + 실리카 0.002%Control + Eugenol 0.002% + Saccharin 0.002% + Fluorine 0.002% + Calcium Carbonate 0.002% + Silica 0.002%
실험 대상자는 치열이 고르고 결손 치아가 없는 치은 염증 환자를 대상으로 연령별 30세부터 50세까지 10세 간격으로 성별에 따라 30명씩 정밀한 구강 검진을 실시하여 120명의 실험대상군을 선별한 후 60명씩 나누어 치은염증 치료효과에 대한 임상실험을 수행하였다. The test subjects were gingival inflammatory patients who had even dentition and no missing teeth. 30 subjects were selected from 30 to 50 years of age, followed by precise oral checkups by 30 people according to gender. A clinical trial was conducted on the treatment effect of gingivitis.
실험 대상군을 실험군과 대조군으로 나누어 식후 2시간 경과 후 잠자기 전에 하루 3회 사용하도록 교육시키고, 치면세마를 실시하여 초기 치은염 지수를 점수화하고 각각의 치약 조성물을 사용하도록 하여 1주, 1개월, 3개월 및 6개월 경과 후 구강검진을 실시하여 치은염지수를 검사하였다. 치은염 지수의 측정방법은 페리오덴탈 프로브(periodontal probe)를 치은 열구 내에 삽입하여 힘을 가하지 않은 상태로 각 치아 주위를 연소하여 탐침하고 30초가 지난 뒤에 출혈된 상태를 측정하여 다음과 같은 방법으로 점수를 기록하여 결과를 얻었다.The experimental group was divided into the experimental group and the control group, and was educated to use 3 times a day before going to sleep after 2 hours after eating, and scored the initial gingivitis index by performing a face wash, and used each toothpaste composition for 1 week, 1 month, 3 After months and 6 months, oral examinations were conducted to examine the gingivitis index. The method of measuring the gingivitis index is by inserting a periodontal probe into the gingival fissure, burning the probe around each tooth without applying force, and measuring the bleeding condition after 30 seconds. Recorded to obtain results.
점수 score 내용Contents
0점0 points 무출혈상태No bleeding condition
1점1 point 정상출혈상태Normal bleeding condition
2점2 points 선상출혈상태Hemorrhage on the ship
3점3 points 치간부위 삼각형 출혈상태Interstitial triangle bleeding condition
4점4 points 치은전체 출혈상태Gingival bleeding
구분division 대조군Control 실험군c1Experiment group c1 실험군c2Experiment group c2 실험군c3Experiment group c3 실험군c4Experimental group c4 실험군c5Experiment group c5 실험군c6Experiment group c6 실험군c7Experiment group c7 실험군c8Experiment group c8 실험군c9Experiment group c9 실험군c10 Experiment group c10
0주0 weeks 1.051.05 1.041.04 1.051.05 1.041.04 1.061.06 1.051.05 1.051.05 1.041.04 1.051.05 1.051.05 1.061.06
1주1 week 1.601.60 1.151.15 1.451.45 1.411.41 1.351.35 1.401.40 1.111.11 1.111.11 1.101.10 1.121.12 1.081.08
1개월1 month 2.632.63 1.171.17 2.002.00 1.181.18 2.012.01 2.102.10 1.151.15 1.151.15 1.151.15 1.161.16 1.101.10
3개월3 months 2.792.79 1.191.19 2.352.35 2.252.25 2.182.18 2.322.32 1.181.18 1.191.19 1.171.17 1.171.17 1.121.12
6개월6 months 2.872.87 1.231.23 2.522.52 2.482.48 2.392.39 2.402.40 1.211.21 1.191.19 1.201.20 1.211.21 1.151.15
실험 결과, 대조군은 치은 염증의 악화와 함께 치은염 지수가 증가한 반면, 사카린, 불소, 탄산칼슘, 실리카 또는 이들의 혼합물에 유게놀을 포함하는 실험군 c5 내지 c10 모두 대조군은 물론 유게놀, 사카린, 불소, 탄산칼슘 또는 실리카 각각 단독처리한 경우(실험군 c1 내지 c5)에 비하여 치은염 지수의 증가가 낮아서 우수한 치은염 개선 효과를 발휘하였고, 특히 유게놀, 사카린, 불소, 탄산칼슘 및 실리카를 모두 포함하는 실험군 c10에서 치은염 지수 증가 정도가 가장 낮고 그 효과 또한 6개월 후에도 우수하게 유지하는 것을 확인하였다.As a result of the experiment, the gingivitis index increased with exacerbation of gingival inflammation in the control group, while in the experimental groups c5 to c10 containing eugenol in saccharin, fluorine, calcium carbonate, silica, or a mixture thereof, both the control group, as well as eugenol, saccharin, fluorine, Compared to the calcium carbonate or silica treatment alone (experimental groups c1 to c5), the gingival index was lowered, thereby exhibiting excellent gingivitis improvement effect. In particular, in experimental group c10 containing all of eugenol, saccharin, fluorine, calcium carbonate, and silica It was confirmed that the degree of gingivitis index increase was the lowest, and the effect was also excellent after 6 months.
[실시예 4] 시린이 현상 억제 정도 비교[Example 4] Comparison of the degree of suppression of syrin
상기에서 제조한 대조군 및 실험군(실시예) 조성물의 시린이 억제 정도를 비교하였다. (표 3 참고)The control and experimental group (Example) composition prepared above was compared to the degree of inhibition of the syringe. (See Table 3)
구체적인 실험 방법은, 지각 과민 치아를 가진 사람으로 이 실험에 참여하기를 동의한 지원자 40명을 연구대상으로 하였으며, 총 연구대상 치아는 80다. 또한, 지원자 중 남자가 20명, 여자가 20명이었고, 연령은 20세에서 50세였다. 연구 대상자들은 치약 내용물을 알지 못하도록 하였고, 총 시험기간은 2주로 하였다. For the specific test method, 40 volunteers who agreed to participate in this experiment as subjects with hypersensitive teeth were studied, and the total number of teeth studied was 80. In addition, there were 20 men and 20 women among the applicants, and the age ranged from 20 to 50 years. The subjects were not allowed to know the contents of the toothpaste, and the total test period was 2 weeks.
온도 자극을 가한 후 환자의 반응을 측정하는 방법으로 시험을 실시하였다. 시험을 실시하기 전에 미리 각 지원자의 지각 과민 치아의 과민부위를 체크하였고, 치아의 시린 부위에 약 5℃의 차가운 물을 스포이드로 떨어뜨려 평점을 한 후 2주간 각각의 조성물을 1일 3회 사용하게 하고, 2주가 지나 다시 약 5℃의의 차가운 물을 스포이드로 떨어뜨려 평점을 하였다. 자극 후 환자의 반응 평점 기준은 다음과 같이 설정하였다. (0점: 아무런 불편감이 없다., 1점: 약간 불편하거나 시리다., 3점: 아프다.). 통계처리는 실험실시 전과 2주 후의 자극 점수를 paired student-t test로 검정하였다.The test was conducted by measuring the patient's response after applying temperature stimulation. Before conducting the test, the hypersensitivity area of each candidate's perceptive hypersensitivity teeth was checked beforehand, and each composition was used 3 times a day for 2 weeks after dropping the cold water of about 5°C into the dropper of the tooth with a dropper for evaluation. After 2 weeks, the water was dropped again to a dropper of about 5°C with a dropper for evaluation. After stimulation, the criteria for the patient's response rating were set as follows. (0 point: no discomfort, 1 point: slightly uncomfortable or cold, 3 point: sick). Statistical treatment was tested by paired student-t test for stimulation scores before and 2 weeks after laboratory.
2주 후의 온도 자극에 대한 반응점수는 다음 표 7과 같다.The response scores for temperature stimuli after 2 weeks are shown in Table 7 below.
구분division 대조군Control 실험군c1Experiment group c1 실험군c2Experiment group c2 실험군c3Experiment group c3 실험군c4Experimental group c4 실험군c5Experiment group c5 실험군c6Experiment group c6 실험군c7Experiment group c7 실험군c8Experiment group c8 실험군c9Experiment group c9 실험군c10 Experiment group c10
0주0 weeks 2.15±0.112.15±0.11 2.14±0.102.14±0.10 2.14±0.092.14±0.09 2.13±0.052.13±0.05 2.14±0.042.14±0.04 2.15±0.112.15±0.11 2.15±0.082.15±0.08 2.14±0.112.14±0.11 2.15±0.012.15±0.01 2.14±0.072.14±0.07 2.13±0.102.13±0.10
2주2 weeks 2.14±0.102.14±0.10 1.85±0.181.85±0.18 1.90±0.111.90±0.11 1.86±0.081.86±0.08 1.91±0.121.91±0.12 1.89±0.051.89±0.05 1.77±0.201.77±0.20 1.75±0.071.75±0.07 1.80±0.111.80±0.11 1.74±0.081.74±0.08 1.65±0.121.65±0.12
유의성valence p>0.05p>0.05 *p<0.05*p<0.05 *p<0.05*p<0.05 *p<0.05*p<0.05 *p<0.05*p<0.05 *p<0.05*p<0.05 *p<0.05*p<0.05 *p<0.05*p<0.05 *p<0.05*p<0.05 *p<0.05*p<0.05 *p<0.05*p<0.05
실험 결과, 대조군은 시린이 지수가 0주 대비하여 0.01점만 감소한 반면, 사카린, 불소, 탄산칼슘, 실리카 또는 이들의 혼합물에 유게놀을 포함하는 실험군 c5 내지 c10 모두 대조군은 물론 유게놀, 사카린, 불소, 탄산칼슘 또는 실리카 각각 단독처리한 경우(실험군 c1 내지 c5)에 비하여 우수한 시린이 개선 효과를 발휘하였고, 특히 유게놀, 사카린, 불소, 탄산칼슘 및 실리카를 모두 포함하는 실험군 c10에서 시린이 지수 감소가 가장 높은 것을 확인하였다.As a result of the experiment, the control group had a decrease in index of only 0.01 points compared to the 0-week index, whereas all of the experimental groups c5 to c10 containing eugenol in saccharin, fluorine, calcium carbonate, silica, or mixtures thereof, as well as the control group, eugenol, saccharin, and fluorine , Compared to calcium carbonate or silica alone (experimental groups c1 to c5), superior syrin showed an improvement effect, and in particular, syrin decreased index in experimental group c10 containing all of eugenol, saccharin, fluorine, calcium carbonate, and silica. Was confirmed to be the highest.
[실시예 5] 구취 제거 효과 실험[Example 5] Bad breath removal effect experiment
상기에서 제조한 대조군 및 실험군(실시예) 조성물의 구취 제거 정도를 비교하였다. (표 3 참고)The degree of bad breath removal of the control group and the experimental group (Example) composition prepared above was compared. (See Table 3)
치아우식증이 없는 남녀 50명을 선정하여 대상 음료에 대하여 교차 반복 실험(Cross-over test)을 실시하였다. 시판하는 마늘분을 물에 분산시켜 24시간 방치한 후 희석하여 할리미터(Halimeter) 측정값이 700ppb 이상이 되도록 하여, 상기 희석액을 구취 유발원으로 사용하였다. 마늘분 희석액 15㎖로 30초간 가글을 한 후 1분 뒤에 할리미터로 구취 정도를 측정한 후, 대조군, 실험군 치약을 사용하여 30초~1분간 양치질하였다. 양치질 후 1분, 5분, 30분 경과 후 할리미터로 구취 정도를 측정하여 구취 억제의 지속여부를 측정하였다. 그 결과는 하기 표와 같다.50 men and women without dental caries were selected and a cross-over test was performed on the target beverage. The commercially available garlic powder was dispersed in water, allowed to stand for 24 hours, and then diluted to obtain a Halimeter measurement value of 700 ppb or more, and the diluted solution was used as a bad breath inducer. Gargle was diluted with 15 ml of garlic powder for 30 seconds, and after 1 minute, the degree of bad breath was measured with a halimeter. After 1 minute, 5 minutes, and 30 minutes after brushing, the degree of bad breath was measured with a halimeter to measure whether or not to suppress bad breath. The results are shown in the table below.
구분 division 대조군Control 실험군c1Experiment group c1 실험군c2Experiment group c2 실험군c3Experiment group c3 실험군c4Experimental group c4 실험군c5Experiment group c5 실험군c6Experiment group c6 실험군c7Experiment group c7 실험군c8Experiment group c8 실험군c9Experiment group c9 실험군c10Experiment group c10
1분1 min 56.7%56.7% 96.1%96.1% 96.5%96.5% 96.3%96.3% 96.8%96.8% 96.4%96.4% 96.4%96.4% 96.0%96.0% 97.0%97.0% 96.1%96.1% 96.2%96.2%
5분5 minutes 46.2%46.2% 84.2%84.2% 80.4%80.4% 83.7%83.7% 82.5%82.5% 81.0%81.0% 86.8%86.8% 85.4%85.4% 85.7%85.7% 86.1%86.1% 90.9%90.9%
30분30 minutes 38.5%38.5% 81.8%81.8% 78.9%78.9% 80.2%80.2% 79.8%79.8% 79.0%79.0% 83.7%83.7% 82.1%82.1% 83.3%83.3% 82.8%82.8% 88.1%88.1%
실험 결과, 사카린, 불소, 탄산칼슘, 실리카 또는 이들의 혼합물에 유게놀을 포함하는 실험군 c5 내지 c10 모두 대조군은 물론 유게놀, 사카린, 불소, 탄산칼슘 또는 실리카 각각 단독처리한 경우(실험군 c1 내지 c5)에 비하여 우수한 구취 제거 효과를 발휘하였고, 특히 유게놀, 사카린, 불소, 탄산칼슘 및 실리카를 모두 포함하는 실험군 c10에서 구취 제거 효과가 가장 우수하고 또한 우수한 효과가 유지되는 것을 확인하였다.As a result of the experiment, saccharin, fluorine, calcium carbonate, silica or a mixture of eugenols in the experimental groups c5 to c10 were treated with eugenol, saccharin, fluorine, calcium carbonate or silica, respectively, as a control group (experimental groups c1 to c5) It exhibited an excellent bad breath removal effect compared to ), and in particular, it was confirmed that the bad breath removal effect was the best and the excellent effect was maintained in the experimental group c10 including all of eugenol, saccharin, fluorine, calcium carbonate, and silica.
이상에서, 출원인은 본 발명의 바람직한 실시 예들을 설명하였지만, 이와 같은 실시예들은 본 발명의 기술적 사상을 구현하는 일 실시예일뿐이며 본 발명의 기술적 사상을 구현하는 한 어떠한 변경예 또는 수정예도 본 발명의 범위에 속하는 것으로 해석되어야 한다.In the above, the applicant has described the preferred embodiments of the present invention, but these embodiments are only one embodiment for implementing the technical concept of the present invention and any modification or modification of the present invention as long as the technical concept of the present invention is implemented It should be construed as being within the scope.
본 발명은 항균 효과가 우수하고, 구취, 치통, 구내염, 치은염, 치주염, 시린이, 치아 우식증, 치주질환, 치수 질환 및 치근단 질환의 예방, 개선 및 치료에 우수한 효과를 발휘하여 구강 위생 조성물로 유용하게 사용될 수 있다.The present invention is excellent as an antibacterial effect, bad breath, toothache, stomatitis, gingivitis, periodontitis, syringitis, dental caries, periodontal disease, ulcer disease and apical diseases, excellent effect in preventing, improving and treating it is useful as an oral hygiene composition Can be used.

Claims (8)

  1. 사카린, 불소, 탄산칼슘 및 실리카로 이루어진 군에서 선택되는 어느 하나 이상 및 유게놀을 유효성분으로 포함하는 구강 위생 조성물.Oral hygiene composition comprising any one or more selected from the group consisting of saccharin, fluorine, calcium carbonate and silica and eugenol as an active ingredient.
  2. 제1항에 있어서, 상기 조성물은 구강 질환 예방, 완화 또는 치료용인 것을 특징으로 하는 구강 위생 조성물.The oral hygiene composition according to claim 1, wherein the composition is for preventing, alleviating or treating oral diseases.
  3. 제2항에 있어서, 상기 구강 질환은 구취, 치통, 구내염, 치은염, 치주염, 시린이, 치아 우식증, 치주질환, 치수 질환 및 치근단 질환으로 이루어진 군에서 선택되는 어느 하나 이상인 것을 특징으로 하는 구강 위생 조성물.The oral hygiene composition according to claim 2, wherein the oral disease is at least one selected from the group consisting of bad breath, toothache, stomatitis, gingivitis, periodontitis, syringitis, dental caries, periodontal disease, pulp disease and apical disease. .
  4. 제1항에 있어서, 상기 사카린, 불소, 탄산칼슘 및 실리카로 이루어진 군에서 선택되는 어느 하나 이상은 유게놀 중량 대비 1: 0.1 내지 10 비율로 포함되는 것을 특징으로 하는 구강 위생 조성물.The oral hygiene composition according to claim 1, wherein at least one selected from the group consisting of saccharin, fluorine, calcium carbonate, and silica is included in a ratio of 1:0.1 to 10 by weight of eugenol.
  5. 제1항에 있어서, 상기 사카린, 불소, 탄산칼슘 및 실리카로 이루어진 군에서 선택되는 어느 하나 이상은 조성물 총 중량 대비 0.001 내지 0.1 중량% 포함되는 것을 특징으로 하는 구강 위생 조성물.The oral hygiene composition according to claim 1, wherein at least one selected from the group consisting of saccharin, fluorine, calcium carbonate, and silica is included in an amount of 0.001 to 0.1% by weight based on the total weight of the composition.
  6. 제1항에 있어서, 상기 유게놀은 조성물 총 중량 대비 0.001 내지 0.1 중량% 포함되는 것을 특징으로 하는 구강 위생 조성물.The oral hygiene composition according to claim 1, wherein the eugenol is contained in an amount of 0.001 to 0.1% by weight based on the total weight of the composition.
  7. 제1항에 있어서, 상기 조성물은 스트렙토코커스(Streptococcus) 속 또는 포피로모나스(Porphyromonas) 속에 항균 효과가 있는 것을 특징으로 하는 구강 위생 조성물.The composition of claim 1, wherein the composition has an antibacterial effect in Streptococcus or Porphyromonas .
  8. 제7항에 있어서, 상기 스트렙토코커스(Streptococcus) 속 또는 포피로모나스(Porphyromonas) 속은 스트렙토코커스 뮤탄스(Streptococcus mutans), 스트렙토코커스 상귀스(Streptococcus sanguis), 스트렙토코커스 상귀니스(Streptococcus sanguinis), 스트렙토코커스 살리바리우스 종 써모필스(Streptococcus salivariussubsp. thermophils), 및 포피로모나스 진지발리스(Porphyromonas gingivalis)로 이루어진 군에서 선택된 하나 이상인 것을 특징으로 하는 구강 위생 조성물.The method of claim 7, wherein the genus Streptococcus or genus Porphyromonas is Streptococcus mutans , Streptococcus sanguis , Streptococcus sanguinis , Streptococcus sanguinis Oral hygiene composition, characterized in that at least one selected from the group consisting of the Streptococcus salivariussubsp. thermophils , and Porphyromonas gingivalis .
PCT/KR2018/016051 2018-12-17 2018-12-17 Oral hygiene composition WO2020130164A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PCT/KR2018/016051 WO2020130164A1 (en) 2018-12-17 2018-12-17 Oral hygiene composition

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/KR2018/016051 WO2020130164A1 (en) 2018-12-17 2018-12-17 Oral hygiene composition

Publications (1)

Publication Number Publication Date
WO2020130164A1 true WO2020130164A1 (en) 2020-06-25

Family

ID=71101411

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2018/016051 WO2020130164A1 (en) 2018-12-17 2018-12-17 Oral hygiene composition

Country Status (1)

Country Link
WO (1) WO2020130164A1 (en)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100327886B1 (en) * 1994-06-29 2002-08-01 라이온 가부시키가이샤 Oral composition
JP2012509893A (en) * 2008-11-25 2012-04-26 ザ プロクター アンド ギャンブル カンパニー Oral care composition having improved aesthetics and fused silica
KR20130027751A (en) * 2011-09-08 2013-03-18 동의대학교 산학협력단 Oral composition containing clove oil or eugenol
US20130295027A1 (en) * 2010-12-07 2013-11-07 Maya Treesa Saji Oral care composition

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100327886B1 (en) * 1994-06-29 2002-08-01 라이온 가부시키가이샤 Oral composition
JP2012509893A (en) * 2008-11-25 2012-04-26 ザ プロクター アンド ギャンブル カンパニー Oral care composition having improved aesthetics and fused silica
US20130295027A1 (en) * 2010-12-07 2013-11-07 Maya Treesa Saji Oral care composition
KR20130027751A (en) * 2011-09-08 2013-03-18 동의대학교 산학협력단 Oral composition containing clove oil or eugenol

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
XU, J.-S.: "The effect of eugenol on the cariogenic properties of streptococcus mutans and dental caries development in rats", EXPERIMENTAL AND THERAPEUTIC MEDICINE, vol. 5, 2013, pages 16 67 - 1670, XP055721102 *

Similar Documents

Publication Publication Date Title
Mandel Antimicrobial mouthrinses: overview and update
Kurian et al. Effect of herbal and fluoride toothpaste on Streptococcus mutans-a comparative study
Adámková et al. Macleya cordata and Prunella vulgaris in oral hygiene products-their efficacy in the control of gingivitis
Saima et al. efficacy of chlorhexidine vs herbal mouthwash in college students: A comparative study
KR102546767B1 (en) Composition for preventing or treating oral diseases
KR20170103476A (en) Composition for prevention or treatment of oral disease comprising ROSAE LAEVIGATAE Extract
KR102509579B1 (en) Oral composition comprising cassava extract
WO2020130164A1 (en) Oral hygiene composition
KR20200050801A (en) Oral composition containing eugenol and bamboo salt
KR20160061852A (en) Oral composition containing both metal chelating agent and isopropylmethylphenol
Hassan et al. Pre-procedural Antimicrobial Mouth Rinse: A Concise Review
KR20170051006A (en) Oral composition containing both isopropylmethylphenol and oral tissue astringent
KR102597684B1 (en) Oral composition comprising amaranth extract
Al-Zarea et al. Efficacy of Myrrh Mouth Rinse vs. Chlorhexidine Mouth Rinse in Maintaining the Soft Tissue Health around Dental Implants: A Comparative Study.
Abdel-Haffiez et al. The effect of miswak varnish on streptococcus mutans count and gingival inflammation in orthodontic patients
KR102379228B1 (en) Oral composition comprising chives extract
KR20170037231A (en) Oral composition comprising purslane extract
KR20230001978A (en) Oral composition comprising hinokitiol
KR102597685B1 (en) Oral composition comprising parsley extract
KR101617845B1 (en) Composition for preventing and improving periodontal disease
Abid et al. Comparative efficacy of the antiplaque effect of natural honey mouthwash and chlorhexidine mouthwash. a randomized controlled trial
KR0138248B1 (en) The oral cavity hygienic compositions
KR100665891B1 (en) Oral hygiene compositions containing hydroxytyrosol
Khan et al. A Randomized Clinical Trial Evaluating the Efficacy of Chlorhexidine Varnish on Streptococcus mutans in Plaque and the Gingival Status in Patients Undergoing Orthodontic Treatment
KR102626864B1 (en) Composition for prevention or treatment of oral disease comprising Shikonin

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18943861

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205A DATED 06/10/2021)

122 Ep: pct application non-entry in european phase

Ref document number: 18943861

Country of ref document: EP

Kind code of ref document: A1